Research programme: monoamine oxidase A inhibitors - CeNeRx BioPharma

Drug Profile

Research programme: monoamine oxidase A inhibitors - CeNeRx BioPharma

Alternative Names: CX 2614; CX009; CX1370

Latest Information Update: 28 Jun 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Krenitsky Pharmaceuticals
  • Developer CeNeRx BioPharma
  • Class Small molecules
  • Mechanism of Action Monoamine oxidase A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Anxiety disorders; Major depressive disorder

Most Recent Events

  • 28 Jun 2013 Discontinued - Preclinical for Anxiety disorders in USA (PO)
  • 28 Jun 2013 Discontinued - Preclinical for Major depressive disorder in USA (PO)
  • 27 Jan 2011 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top